The rapid integration of artificial intelligence into clinical decision-making represents both unprecedented opportunities and significant risks. Globally, AI systems are implemented increasingly to diagnose diseases, predict patient outcomes, and guide treatment protocols. Despite this, our regulatory frameworks remain dangerously antiquated and designed for an era of static medical devices rather than adaptive, learning algorithms.

The stark disparity between healthcare AI innovation and regulatory oversight constitutes an urgent public health concern. Current fragmented approaches leave critical gaps in governance, allowing AI-driven diagnostic and decision-support tools to enter clinical settings without adequate safeguards or clear accountability structures. We must establish comprehensive, dynamic oversight mechanisms that evolve alongside the technologies they govern. The evidence demonstrates that one-time approvals and static validation protocols are fundamentally insufficient for systems that continuously learn and adapt. The time for action is now, as 2025 is anticipated to be pivotal for AI validation and regulatory approaches.

We therefore in this report herein we propose a three-pillar regulatory framework:

First, nations ought to explore implementing risk-based classification systems that apply proportionate oversight based on an AI system’s potential impact on patient care. High-risk applications must face more stringent monitoring requirements with mechanisms for rapid intervention when safety concerns arise.

Second, nations must eventually mandate continuous performance monitoring across healthcare institutions through automated systems that track key performance indicators, detect anomalies, and alert regulators to potential issues. This approach acknowledges that AI risks are often silent and systemic, making them particularly dangerous in healthcare contexts where patients are inherently vulnerable.

Third, establish regulatory sandboxes with strict entry criteria to enable controlled testing of emerging AI technologies before widespread deployment. These environments must balance innovation with rigorous safeguards, ensuring new systems demonstrate consistent performance across diverse populations.

Given the global nature of healthcare technology markets, we must pursue international regulatory harmonization while respecting regional resource constraints and cultural contexts.